Lorenzo Tonialini
Bari, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Diagnostic and therapeutic pathways for lymphoma patients: expert consensus through Nominal Group Technique and Delphi methodology.
Journal: Frontiers in oncology
Published: May 12, 2025
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin's lymphoma.
Journal: Annals of hematology
Published: June 21, 2022
Real-life efficacy and safety of idelalisib in 55 double-refractory follicular lymphoma patients.
Journal: British journal of haematology
Published: June 02, 2022
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Journal: Annals of hematology
Published: January 21, 2020
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience.
Journal: American journal of hematology
Published: May 18, 2018
Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.
Journal: Hematological oncology
Published: April 30, 2018
Interesting activity of pegylated liposomal doxorubicin in primary refractory and multirelapsed Hodgkin lymphoma patients: bridge to transplant.
Journal: Hematological oncology
Published: November 23, 2017
Long-Term Responders After Brentuximab Vedotin: Single-Center Experience on Relapsed and Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma Patients.
Journal: The oncologist
Published: March 16, 2016
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
Journal: Cancer medicine
Published: December 01, 2015
Showing 1-11 of 11
Last Updated: 09/26/2026